AAPL vs LLY: Which Is the Better Buy?
Side-by-side comparison of Apple Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Apple Inc. · Technology
$337.02
+9.9% upside to fair value
Med Conviction
Grade B
High Quality
VS
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
AAPL has more upside to fair value
(+9.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AAPL |
LLY |
| Current Price |
$337.02 |
$1,183.72 |
| Fair Value Estimate |
$370.54 |
$1,208.00 |
| Upside to Fair Value |
+9.9%
|
+2.1%
|
| Market Cap |
$4,949.9B |
$1,114.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
29.6x
|
26.8x
|
| Price / Sales |
10.6x
|
14.0x
|
| Price / FCF |
36.2x
|
52.7x
|
| Revenue Growth YoY |
+16.4%
|
+47.7%
|
| Gross Margin |
48.7%
|
83.4%
|
| Operating Margin |
33.2%
|
49.7%
|
| Return on Equity |
137.2%
|
92.6%
|
| Dividend Yield |
0.31% |
0.57% |
| FCF Yield |
2.76%
|
1.9%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Apple Inc. is a global consumer-electronics and services platform whose hardware lineup (iPhone, Mac, iPad, wearables) and digital ecosystem (App Store, Apple Music, iCloud, Apple Pay, advertising) generated $31.78 of revenue per share and $9.30 of free cash flow per share on a trailing basis, with TTM gross margin of 48.7%, operating margin of 33.2%, net margin of 27.6%, and ROE of 137.2%. Busin…
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Accumulation Zones
| Metric |
AAPL |
LLY |
| Zone Low |
$277.91 |
$906.00 |
| Zone High |
$314.96 |
$1,026.80 |
| In Buy Zone? |
No
|
No
|